DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Avoro Capital Advisors LLC
Avoro Capital Advisors LLC
Avoro Capital Advisors is a global firm focused on funding & investments in biotechnology, life sciences, and specialty therapeutics. Contact us today!
venture manager, reported GAV $166M across 1 vehicles
Importance
36
elevated
Active deployment
30
moderate
Emerging
0
low
Completeness
69
high
Freshness
100
high
Research priority
13
low
Identity and regulatory footprint
- Headquarters
- New York, NYadviserinfo.sec.gov
- Office address
- 110 GREENE STREET, SUITE 800, New York, NY, 10012adviserinfo.sec.gov
- Business phone
- 212-937-4970adviserinfo.sec.gov
- Website
- HTTP://www.avorocapital.com
- SEC adviser type
- registered investment adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Mar 5, 2026
- Private funds reported
- 2 (1 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $14Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Regulatory AUM
- $14Bthe adviser's RAUM, a regulatory measure, never a fund size
- Employees
- 19
- Owners on Schedule A
- Avoro Capital GP LLC (General Partner), F; Avoro Capital L.P. (Direct Owner), E
- business email
- info@avorocapital.comavorocapital.compublished by the subject
- business phone
- 212-937-4970adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
54 observed deals
Stated (the firm’s website)
- Sectors
- biotech
- Stages
- not stated or not yet read
- Geography
- global, new york
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 93%Biotechnology 6%Pharmaceuticals 2%
lead rate n/afollow-on rate n/anew logos, 12 months 54
Funds and vehicles
1 reported, 2 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Avoro Ventures Fund L.P. | Fund | 2021 form d first sale | Mature | $166M Jun 4, 2024 | 48 | $178M | Jul 22, 2021 |
| Venbio Global Strategic Fund II, L.P. | Fund | 2016 adv first reported | Wound down | $315M Aug 21, 2017 | 27 | unknown | unknown |
| Venbio Global Strategic Fund, L.P. | Fund | unknown | Wound down | $179M Aug 21, 2017 | 5 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
20 current, 4 departed
Max Isberg
AnalystSenior Analyst
Billy Smith
AssociateAssociate
David Xiang
AssociateMD MPH | Associate
Susana Wilson Hawken
AssociatePhD | Associate
Jenna McElhinney
Investor relationsManager | Investor Relations & Marketing
Lauren Godlasky
Investor relationsHead of Investor Relations & Marketing
Behzad Aghazadeh
Managing partnerPhD | Managing Partner & Portfolio Manager
Behzad Aghazadeh
PartnerMember · since May 1, 2019
Garheng Albert Kong
PartnerMember · since May 1, 2019
Mark Chin
PartnerInvestment Partner - Avoro Ventures
Uya Chuluunbaatar
PartnerPhD | Investment Partner – Avoro Ventures
Bryan Phillips
Platform and operationsJD | Deputy Chief Compliance Officer
Corie Hansen
Platform and operationsOffice Manager / Executive Assistant
Diane Chien
Platform and operationsCPA | Hedge Fund Controller
Molly Reichhard
Platform and operationsReceptionist / Executive Assistant
Neil Cammarosano
Platform and operationsCPA | Chief Financial Officer
Neil Cammarosano
Platform and operationsChief Financial Officer · since May 1, 2024
Scott Andrew Epstein
Platform and operationsChief Operating Officer And Chief Compliance Officer · since Jun 1, 2014
Scott Epstein
Platform and operationsPartner, Chief Operating Officer & Chief Compliance Officer
Matthew Canver
PrincipalMD/PhD | Director
4 departed (kept with end dates)
- Corey S. Goodman · Manager · Jan 1, 2013 to Sep 28, 2017 Inference
- Konrad Hans Vonemster · Manager · Sep 1, 2009 to Jan 13, 2015 Inference
- Paul Alan Brooke · Manager · Jan 1, 2013 to Mar 29, 2016 Inference
- Robert Adelman · Manager · Jan 1, 2013 to Sep 28, 2017 Inference
Investments on record
54 edges, 54 companies, 0 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
13 relationships from shared deals, counted for the whole firm
Sofinnova Investments, Inc. 7 shared · strongVivo Capital, LLC 5 shared · strongArch Venture Partners 2 shared · recurringOmega Fund Management, LLC 2 shared · recurringNEW Leaf Venture Partners 1 shared · one timeThe Column Group 1 shared · one timeCivilization Ventures Management, LLC 1 shared · one timeLumia Capital 1 shared · one timeHealthCap 1 shared · one timeRA Capital Management, LP 1 shared · one timeDallas Venture Capital 1 shared · one timePledge Ventures Ltd 1 shared · one timeBiogeneration III Services B.V. 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
15 dated events
- May 1, 2024Neil Cammarosano joined Schedule A of Avoro Capital Advisors LLC as Chief Financial Officer
- Mar 23, 2021Venbio Global Strategic Fund II, L.P. no longer reported on Form ADV by Avoro Capital Advisors LLCFund no longer reportedFundsInferenceVenbio Global Strategic Fund II, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 23, 2021Avoro Ventures Fund L.P. first reported on Form ADV by Avoro Capital Advisors LLC (Venture Capital Fund), GAV $125,000,000Fund first reported on Form ADVFundsFactAvoro Ventures Fund L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 23, 2021Venbio Global Strategic Fund, L.P. no longer reported on Form ADV by Avoro Capital Advisors LLCFund no longer reportedFundsInferenceVenbio Global Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 1, 2019Garheng Albert Kong joined Schedule A of Venbio Select Advisor LLC as Member
- Sep 28, 2017Robert Adelman (Manager) no longer on Schedule A of Venbio Select Advisor LLC
- Sep 28, 2017Corey S. Goodman (Manager) no longer on Schedule A of Venbio Select Advisor LLC
- Mar 29, 2016Paul Alan Brooke (Manager) no longer on Schedule A of Venbio Select Advisor LLC
- Jan 13, 2015Konrad Hans Vonemster (Manager) no longer on Schedule A of Venbio Select Advisor LLC
- Jun 1, 2014Scott Andrew Epstein joined Schedule A of Venbio Select Advisor LLC as Chief Financial Officer And Chief Compliance Officer
- Apr 1, 2013Robert Adelman joined Schedule A of Venbio Select Advisor LLC as Chief Compliance Officer
- Jan 1, 2013Paul Alan Brooke joined Schedule A of Venbio Select Advisor LLC as Manager
- Jan 1, 2013Corey S. Goodman joined Schedule A of Venbio Select Advisor LLC as Manager
- Feb 22, 2012Venbio Select Advisor LLC first filed Form ADV (IA)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jul 1, 2011Behzad Aghazadeh joined Schedule A of Venbio Select Advisor LLC as Portfolio Manager
Classification history
- Sep 12, 2026Institutional venture firm (probable, 80%, cls-1)venture manager, reported GAV $166M across 1 vehicles
Evidence
68 observations from 3 sources